The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global cancer vaccines market reached a value of US$ 5.43 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 10.72 Billion by 2027, exhibiting a CAGR of 11.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Cancer is a malignant tumor caused by the uncontrollable growth of abnormal cells in the body. It can be treated through the use of various medications and vaccines. Between these, vaccines are broadly categorized into preventive and therapeutic. Preventive cancer vaccines are deployed for eliminating cancer caused by oncovirus and protecting from human papillomavirus (HPV), whereas therapeutic vaccines aid in stimulating the individual adaptive immune systems by using tumor antigens. At present, cancer vaccines are commercially available in varying types, such as antigen, dendritic cell, and anti-idiotype.
The increasing prevalence of cancer, especially due to the rising consumption of tobacco-based products and evolving lifestyles is currently driving the cancer vaccines market growth. In line with this, favorable initiatives undertaken by the government bodies of several nations for introducing novel cancer vaccines, along with extensive fundings in the field of viral recombinant cancer vaccines are further facilitating the widespread adoption of these vaccines in the healthcare sector. In line with this, the extensive utilization of United States Food and Drug Administration (US FDA) approved vaccines, including human papillomavirus vaccine (HPV) and hepatitis B vaccine (HBV) to reduce the risk of certain types of cancer, such as liver cancer, is contributing to the market growth. The market is also significantly driven by rapid technological advancements focusing on the development of effective and specific cancer treatments. Other factors, such as improving healthcare infrastructure, rising geriatric population, who are susceptible to various chronic ailments, including cancer, and growing consumer awareness regarding the symptoms and the available treatment options, are creating a positive outlook for the market further across the globe.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer vaccines market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, technology, indication and end user.
Breakup by Type:
Breakup by Technology:
Breakup by Indication:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Anixa Biosciences Inc., Dendreon Pharmaceuticals LLC, Dynavax Technologies Corporation, GSK plc, Merck & Co. Inc., Moderna Inc., OSE Immunotherapeutics, Providence Therapeutics, Sanofi S.A., UbiVac Inc. and Vaccitech plc.
|Base Year of the Analysis||2021|
|Segment Coverage||Type, Technology, Indication, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Anixa Biosciences Inc., Dendreon Pharmaceuticals LLC, Dynavax Technologies Corporation, GSK plc, Merck & Co. Inc., Moderna Inc., OSE Immunotherapeutics, Providence Therapeutics, Sanofi S.A., UbiVac Inc. and Vaccitech plc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Disinfection Robots Market by Product Type (UV-Disinfection Robot, Hydrogen Peroxide Vaporization Robot (HPV) and Others), Technology (Fully Autonomous Disinfection Robots, Semi-Autonomous Disinfection Robots), End User (Hospitals and Clinics, Research Institutes, and Others) and Region 2023-2028
Medication Management Market by Software (Computerized Physician Order Entry System, Clinical Decision Support System, Administration Software, Inventory Management System, Automated Dispensing Systems, Assurance System), Services (Medication Analytics Services, Point-Of-Care Verification Services, Adverse Drug Event (ADE) Surveillance Services), Mode of Delivery (Web-based, Cloud-based, On-premises), End User (Pharmacies, Hospitals and Others) and Region 2023-2028
Preoperative Surgical Planning Software Market by Type (Off-premises Software, On-premises), Application (Orthopedic Surgery, Neurosurgery, Dental & Orthodontics Application, and Others), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at